"We are very pleased with the progress of the optimization work and we can update that we have moved into the final phase of bioinformatics analysis.  We will, as planned, be able to communicate the results end of May/beginning of June.  At this time, we are also pleased to report that the process of obtaining fresh, high-quality samples needed for the next steps after the optimization is moving forward successfully. We have and are currently collecting fresh blood samples from three (3) sites and continue to work on finalizing agreements with another three - five (3-5) sites. This will ensure enough samples for the Commercial Test Model Study, Verification and Validation process leading to sales start," commented Mats Grahn, CEO, Immunovia. Mr. Grahn continued, "These sites are both in North America and Europe, which is important as it gives us the genetic variability that best mirrors our commercialization conditions". 

The steps to market remain unchanged. The completion of the optimization work and finalizing the agreements for the supply of fresh blood samples is a prerequisite for being able to update time to market.  As previously communicated, after the optimization follow the  Commercial Test Model Study Test, Verification and Validation steps.
Results of the optimization work will be communicated end of May/beginning of June and will also include more details on milestones to commercialization and sales start.

Immunovia's CEO, Mats Grahn will host a telephone conference (in English) on April 29, 2019, 3:00 p.m. CET to present Immunovia, comment on the interim report for the period January-March 2019, give an update from the Annual General Meeting on April 26, and to answer questions and provide additional details on the optimization work, including a slide presentation.  Please call in a few minutes in advance. 

Participant dial in number 

BE: +3226200547 
DK: +4578150110 
FR: +33170750775
DE: +496913803452 
NO: +4723500236 
SE: +46856642695 
CH: +41225675632 
NL: +31207219495 
UK: +443333009274 
US: +18335268383

Weblink 

https://tv.streamfabriken.com/immunovia-q1-2019 

There will be an archived reply of the live call available on Immunovia's IR page: http://immunovia.com/investors/financial-reports/ for those who want to listen to the telephone conference afterwards. The file will be available within two hours after the conference has ended.

For more information, please contact:
Julie Silber
Director of Investor Relations
Email: julie.silber@immunovia.com
Tel: +46 7 93 486 277

This is information that Immunovia is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14.00 CET on Monday, April, 29, 2019.

About Immunovia
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia's core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood-based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring.
(Source: www.immunovia.com)

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

About Pancreatic Cancer

Pancreatic Cancer is one of the most deadly and difficult to detect cancers, as the signs and symptoms are diffuse and similar to other diseases. There are more than 40,000 deaths and over 50,000 new cases diagnosed each year in the U.S. alone, and the five-year survival rate for pancreatic cancer is currently 5-8 %. It is predicted to become the second leading cause of cancer death by 2020. However, because resection is more successful in stage I/II, early diagnosis can significantly improve pancreatic cancer patients' 5-year survival rates from 5-8 % to up to 49%.

                                                                                                 ###